Advantages and Disadvantages of Hyperbaric Oxygen Treatment in Mice with Obesity Hyperlipidemia and Steatohepatitis

Table 1

The serum lipid.

	Cholesterol (mg/dL)					TG (mg/dL)
Sample	Total	CM; (>80 nm)	VLDL; (30–80 nm)	LDL; (16–30 nm)	HDL; (8–16 nm)	Total	CM; (>80 nm)	VLDL; (30–80 nm)	LDL; (16–30 nm)	HDL; (8–16 nm)
HBOT-1	217.70	3.06	15.48	52.19	146.98	165.50	27.59	84.87	19.04	34.00
HBOT-2	155.22	0.53	4.36	26.41	123.92	36.12	2.95	17.80	10.21	5.16
HBOT-3	111.52	1.05	6.32	15.74	88.41	51.20	6.58	27.34	9.82	7.47
HBOT-4	107.11	1.13	9.94	13.90	82.14	90.72	9.38	59.87	13.56	7.90
HBOT-5	166.60	0.88	11.72	37.44	116.56	78.42	5.79	49.83	15.12	7.67
HBOT-6	205.66	0.39	3.28	66.57	135.42	24.46	1.44	9.68	7.69	5.64
HBOT-7	207.75	0.25	3.72	59.95	143.82	22.55	0.86	9.86	7.63	4.20
HBOT-8	193.78	0.43	3.82	57.63	131.90	21.62	0.74	9.65	6.40	4.84
HBOT-9	245.03	1.73	9.21	98.57	135.53	71.69	12.76	36.07	12.66	10.20
HBOT-10	140.91	0.40	5.65	22.38	112.48	53.57	3.08	30.37	14.58	5.54
Ave	175.13	0.99	7.35	45.08	121.72	61.59	7.12	33.53	11.67	9.26
Cont-1	166.30	0.19	15.56	34.86	115.69	63.74	1.82	49.69	8.31	3.92
Cont-2	128.11	0.03	3.61	24.80	99.67	28.63	0.36	18.14	6.81	3.32
Cont-3	324.08	0.03	10.41	94.72	218.93	86.88	0.58	60.97	16.51	8.82
Cont-4	189.40	0.04	7.25	32.47	149.63	52.36	0.39	34.64	11.99	5.34
Cont-5	133.15	0.05	6.09	20.81	106.20	35.94	0.46	26.42	5.94	3.13
Cont-6	165.41	0.14	10.74	33.28	121.25	40.28	0.80	28.52	8.25	2.72
Cont-7	193.70	0.03	3.93	50.60	139.13	33.99	0.00	14.84	8.96	10.19
Cont-8	183.32	0.02	7.60	34.33	141.38	37.74	0.03	25.99	7.88	3.84
Cont-9	252.71	0.11	13.02	47.22	192.36	64.42	0.93	49.29	10.44	3.76
Ave	192.91	0.07	8.69	41.45	142.69	49.33	0.60	34.28	9.45	5.00